Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154423 | 1.00 | CHRM2 (0.62) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL4246608 | 0.99 | CHRM2 (0.61) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL4244379 | 0.99 | CHRM2 (0.61) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL4246589 | 0.99 | CHRM2 (0.61) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| SCHEMBL17120954 | 0.95 | DRD3 (0.57) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| SCHEMBL3162438 | 0.95 | CHRM2 (0.60) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL4249169 | 0.94 | CHRM2 (0.59) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| SCHEMBL3438788 | 0.94 | HTR1A (0.56) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| Fumaric Acid SCHEMBL4245791 | 0.94 | CHRM2 (0.56) | CHRM2HTR1ASLC6A4DRD3KCNH2 | |
| Fumaric Acid SCHEMBL4245795 | 0.94 | CHRM2 (0.56) | CHRM2HTR1ASLC6A4DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2921168-B1 | ASSOCIATION OF N-{[(7S)-3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL]METHYL}-3-(7,8-DIMETHOXY-1,2,4,5-TETRAHYDRO-3H-3-BENZAZEPIN-3-YL)-N-METHYL-3-OXO-1-PROPANAMINE AND PERINDOPRIL | SERVIER LAB (FR) | 2016-04-13 | — | — | EP | claimed |
| EP-2921168-A1 | USE OF THE COMBINATION OF A SINUS CURRENT IF INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR TREATING CARDIAC INSUFFICIENCY | Les Laboratoires Servier (FR) | 2015-09-23 | — | — | EP | claimed |
| EP-2404600-B1 | Use of the combination of a sinus current If inhibitor and an inhibitor of the angiotensin conversion enzyme for treating cardiac insufficiency with preserved systolic function | SERVIER LAB (FR) | 2015-05-27 | — | — | EP | claimed |
| EP-2404600-A1 | Use of the combination of a sinus current If inhibitor and an inhibitor of the angiotensin conversion enzyme for treating cardiac insufficiency | Les Laboratoires Servier (FR) | 2012-01-11 | — | — | EP | claimed |
| WO-2011157908-A1 | USE OF THE COMBINATION OF AN INHIBITOR OF THE IF CURRENT OF THE SINOATRIAL NODE AND AN INHIBITOR OF THE ANGIOTENSIN-CONVERTING ENZYME FOR TREATING HEART FAILURE | LES LABORATOIRES SERVIER (FR) | 2011-12-22 | — | — | WO | claimed |
| US-20110306598-A1 | Use of the association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure | LES LABORATOIRES SERVIER (FR) | 2011-12-15 | — | — | US | claimed |
| EP-2921168-B1 | ASSOCIATION OF N-{[(7S)-3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL]METHYL}-3-(7,8-DIMETHOXY-1,2,4,5-TETRAHYDRO-3H-3-BENZAZEPIN-3-YL)-N-METHYL-3-OXO-1-PROPANAMINE AND PERINDOPRIL | SERVIER LAB (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2921168-B1 | ASSOCIATION OF N-{[(7S)-3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL]METHYL}-3-(7,8-DIMETHOXY-1,2,4,5-TETRAHYDRO-3H-3-BENZAZEPIN-3-YL)-N-METHYL-3-OXO-1-PROPANAMINE AND PERINDOPRIL | SERVIER LAB (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2921168-B1 | ASSOCIATION OF N-{[(7S)-3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-1,3,5-TRIEN-7-YL]METHYL}-3-(7,8-DIMETHOXY-1,2,4,5-TETRAHYDRO-3H-3-BENZAZEPIN-3-YL)-N-METHYL-3-OXO-1-PROPANAMINE AND PERINDOPRIL | SERVIER LAB (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2921168-A1 | USE OF THE COMBINATION OF A SINUS CURRENT IF INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR TREATING CARDIAC INSUFFICIENCY | Les Laboratoires Servier (FR) | 2015-09-23 | — | — | EP | disclosed |
| EP-2921168-A1 | USE OF THE COMBINATION OF A SINUS CURRENT IF INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR TREATING CARDIAC INSUFFICIENCY | Les Laboratoires Servier (FR) | 2015-09-23 | — | — | EP | disclosed |
| CN-104906579-A | Use of the association of a sinus node If current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure | SERVIER LAB | 2015-09-16 | — | — | CN | disclosed |
| EP-2404600-B1 | Use of the combination of a sinus current If inhibitor and an inhibitor of the angiotensin conversion enzyme for treating cardiac insufficiency with preserved systolic function | SERVIER LAB (FR) | 2015-05-27 | — | — | EP | disclosed |
| WO-2011157908-A1 | USE OF THE COMBINATION OF AN INHIBITOR OF THE IF CURRENT OF THE SINOATRIAL NODE AND AN INHIBITOR OF THE ANGIOTENSIN-CONVERTING ENZYME FOR TREATING HEART FAILURE | LES LABORATOIRES SERVIER (FR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157908-A1 | USE OF THE COMBINATION OF AN INHIBITOR OF THE IF CURRENT OF THE SINOATRIAL NODE AND AN INHIBITOR OF THE ANGIOTENSIN-CONVERTING ENZYME FOR TREATING HEART FAILURE | LES LABORATOIRES SERVIER (FR) | 2011-12-22 | — | — | WO | disclosed |
| CN-102284060-A | Sinus node IfUse of a combination of a current inhibitor and an angiotensin converting enzyme inhibitor for the treatment of heart failure | — | 2011-12-21 | — | — | CN | disclosed |
| US-20110306598-A1 | Use of the association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure | LES LABORATOIRES SERVIER (FR) | 2011-12-15 | — | — | US | disclosed |
| US-20110306598-A1 | Use of the association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure | LES LABORATOIRES SERVIER (FR) | 2011-12-15 | — | — | US | disclosed |
| US-8076325-B2 | 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306598-A1 | Use of the association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure | ACE, KCNN4, AGTR1 | CHRM2 412/4885HTR1A 447/4885SLC6A4 1502/4885 |
| US-20090069296-A1 | 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them | OXER1, NR1H3, OXSR1 | CHRM2 72/4885HTR1A 61/4885SLC6A4 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.